Fatty liver disease medication may have no effect
Tuesday, January 13, 2009 - 17:21
in Health & Medicine
A new randomized, prospective trial has shown that orlistat, a commonly prescribed inhibitor of fat absorption, does not help patients with fatty liver disease (FLD) lose weight, nor does it improve their liver enzymes or insulin resistance. These findings are in the January issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).
Read the whole article on Physorg
More from Physorg
Related
- Fatty liver disease medication may have no effectTue, 13 Jan 2009, 16:57:23 EST
- Exercise helps patients with non-alcoholic fatty liver diseaseWed, 1 Jul 2009, 13:10:16 EDT
- Intestinal bacteria associated with non-alcoholic fatty liver diseaseFri, 29 May 2009, 9:44:52 EDT
- Normal ALT levels may mask advanced fibrosis in liver disease patientsThu, 4 Sep 2008, 16:08:28 EDT
- Regular aerobic exercise reduces health concerns associated with fatty liverWed, 9 Sep 2009, 10:30:47 EDT